Product Pathways - Tyrosine Kinase / Adaptors
SignalSlide® Phospho-ErbB Family IHC Controls #8117
Custom Ordering Details
Sections are cut freshly upon ordering. Domestic: Please allow up to three business days for your order to be processed and shipped. International: Please allow up to one week for your order to be processed and shipped.
Each control slide contains formalin-fixed and paraffin-embedded SK-BR-3 cells, untreated and EGF-treated, that can serve as a control for immunostaining. Western blot analysis was performed on extracts derived from the same cells to verify treatment efficacy.
Immunohistochemical analysis of paraffin-embedded SK-BR-3 cell pellets, either untreated (upper) or hEGF-treated #8916 (lower), using Phospho-EGF Receptor (Tyr1068) (D7A5) XP® Rabbit mAb #3777, Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb #2243, Phopho-HER3/ErbB3 (Tyr1289) (D1B5) Rabbit mAb #2842 or EGF Receptor (D38B1) XP® Rabbit mAb #4267. Cell pellets are provided in the SignalSlide® ErbB Family IHC Controls.
These slides are intended for use in immunohistochemical assays. Please see our website for a list of companion products that can be used with these slides.
- 8111 SignalStain® Phospho-ErbB Family IHC Sampler Kit
- 2243 Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb
- 4290 HER2/ErbB2 (D8F12) XP® Rabbit mAb
- 2165 HER2/ErbB2 (29D8) Rabbit mAb
- 2242 HER2/ErbB2 Antibody
- 2842 Phospho-HER3/ErbB3 (Tyr1289) (D1B5) Rabbit mAb
- 4791 Phospho-HER3/ErbB3 (Tyr1289) (21D3) Rabbit mAb
- 3777 Phospho-EGF Receptor (Tyr1068) (D7A5) XP® Rabbit mAb
- 4407 Phospho-EGF Receptor (Tyr1173) (53A5) Rabbit mAb
- 4267 EGF Receptor (D38B1) XP® Rabbit mAb
- 8112 SignalStain® Antibody Diluent
- 8114 SignalStain® Boost IHC Detection Reagent (HRP, Rabbit)
- 8059 SignalStain® DAB Substrate Kit
- 9997 Tris Buffered Saline with Tween 20 (TBST-10X)
- 5425 Normal Goat Serum
The epidermal growth factor (EGF) receptor is a 170 kDa transmembrane tyrosine kinase that belongs to the HER/ErbB protein family. Ligand binding results in receptor dimerization, autophosphorylation, activation of downstream signaling and lysosomal degradation (1,2). EGFR is phosphorylated on multiple tyrosine residues, each of which leads to activation of a specific downstream pathway. Major residues involved in EGFR signaling include: Tyr845, Tyr992, Tyr1045, Tyr1068, Tyr1148 and Tyr1173 (2-9). Phosphorylation of EGFR at specific serine and threonine residues attenuates EGFR kinase activity. EGFR carboxy-terminal residues Ser1046 and Ser1047 are phosphorylated by CaM kinase II; a mutation to either of these serines results in upregulated EGFR tyrosine autophosphorylation (10).The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (11). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (12). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers, making it a key therapeutic target (13). ErbB2 has several key residues that are phosphorylated upon its activation including Tyr877, Tyr1221/1222 and Tyr1248 (11,14).HER3/ErbB3 is a member of the ErbB receptor protein tyrosine kinase family that lacks tyrosine kinase activity. Tyrosine phosphorylation of ErbB3 depends on its association with other ErbB tyrosine kinases. Ligand binding promotes formation of a heterodimer containing ErbB3 and another ErbB protein and subsequent tyrosine phosphorylation of ErbB3 by the activated ErbB kinase (15,16). At least nine putative carboxy-terminal tail tyrosine phosphorylation sites are found in ErbB3, including Tyr1222 and Tyr1289 (17). ErbB3 may function as an oncogenic unit together with other ErbB members in tumor development; ErbB2 requires ErbB3 to drive breast tumor cell proliferation (18). A novel anti-tumor strategy involves inhibiting the interaction between ErbB3 and ErbB tyrosine kinases.
- Hackel, P.O. et al. (1999) Curr Opin Cell Biol 11, 184-9.
- Zwick, E. et al. (1999) Trends Pharmacol Sci 20, 408-12.
- Cooper, J.A. and Howell, B. (1993) Cell 73, 1051-4.
- Hubbard, S.R. et al. Nature 372, 746-54.
- Biscardi, J.S. et al. (1999) J Biol Chem 274, 8335-43.
- Emlet, D.R. et al. (1997) J Biol Chem 272, 4079-86.
- Levkowitz, G. et al. (1999) Mol Cell 4, 1029-40.
- Ettenberg, S.A. et al. (1999) Oncogene 18, 1855-66.
- Rojas, M. et al. (1996) J Biol Chem 271, 27456-61.
- Feinmesser, R.L. et al. (1999) J Biol Chem 274, 16168-73.
- Muthuswamy, S.K. et al. (1999) Mol Cell Biol 19, 6845-57.
- Qian, X. et al. (1994) Proc Natl Acad Sci U S A 91, 1500-4.
- Dittadi, R. and Gion, M. (2000) J Natl Cancer Inst 92, 1443-4.
- Kwon, Y.K. et al. (1997) J Neurosci 17, 8293-9.
- Yarden, Y. and Sliwkowski, M.X. (2001) Nat Rev Mol Cell Biol 2, 127-37.
- Guy, P.M. et al. (1994) Proc Natl Acad Sci U S A 91, 8132-6.
- Kim, H.H. et al. (1994) J Biol Chem 269, 24747-55.
- Holbro, T. et al. (2003) Proc Natl Acad Sci U S A 100, 8933-8.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.